profit from every $100 of sales.
$0$100
Progyny
$36.18-1.09% today
+48.2% in 1 year
1-year low $16.301-year high $36.58
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $45.53 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Progyny sold, what it kept, and what it did with the cash.
Sales went from $787 million in 2022 to $1.29 billion in 2025, with $58.5 million of profit last year.
SalesProfit
Progyny handed back 43% of the cash it generated last year.
Buybacks $82M
Free cash flow 2025$192M
Bought back its own shares$82M
Paid as dividends–
Cash vs. debt$112M vs. $28M
Progyny vs. similar companies
Progyny grows in the middle of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Progyny | 45.5× · Expensive | ||
 GE HealthCare Technologies | 18.0× · Fair price | ||
 BrightSpring Health Services | 74.3× · Very expensive | ||
 Tempus AI | No profit yet | ||
 HealthEquity | 39.8× · Expensive |
AI analysis
An AI analyst reads Progyny's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 787 | 1,089 | 1,167 | 1,289 | |
| 167 | 239 | 253 | 304 | |
| 23 | 62 | 67 | 85 | |
| 25 | 64 | 71 | 90 | |
| 30 | 62 | 54 | 59 | |
| 0.30 | 0.62 | 0.57 | 0.65 | |
| 21.3% | 21.9% | 21.7% | 23.6% | |
| 3.0% | 5.7% | 5.8% | 6.6% | |
| 3.9% | 5.7% | 4.7% | 4.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 543 | 757 | 607 | 742 |
| Cash | 120 | 97 | 162 | 112 |
| Total debt | 8 | 19 | 19 | 28 |
| Total liabilities | 166 | 203 | 185 | 226 |
| 377 | 553 | 422 | 516 | |
| 100 | 101 | 95 | 90 | |
| 4.8% | 8.6% | 12.1% | 12.4% | |
| 8.1% | 11.2% | 12.9% | 11.3% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 80 | 189 | 179 | 210 | |
| 3 | 4 | 5 | 18 | |
| 77 | 185 | 174 | 192 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | 300 | 82 | |
| 101 | 123 | 128 | 132 |
Valuation
- 45.5×
- 30.9×
- 1.55
- 4.7×
- 2.1×
- 13.9×
- 28.6×
- 7.2%
- 2.2%
- 0.0%
Profitability
- 23.6%
- 6.6%
- 4.5%
- 8.4%
- 13.2%
- 13.4%
- 13.3%
- 9.7%
- 20.9%
- –
Growth
- +17.9%
- +29.4%
- +10.4%
- –
- −1.1%
Financial health
- -1.0×
- 0.06
- 3.9%
- –
- 2.13
- 2.13
- 1.85
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 17%of 952
Bottom 41%of 884
Bottom 27%of 601
Top 30%of 886
Top 13%of 987
What analysts expect
- Average price target
- $30.80
- Range
- $28.00 – $35.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | 0.29 | 0.26 | +13.3% |
| Feb 26, 2026 | 0.15 | 0.15 | +2.0% |
| Nov 6, 2025 | 0.45 | 0.39 | +15.4% |
| Aug 7, 2025 | 0.48 | 0.44 | +9.1% |
| May 8, 2025 | 0.48 | 0.45 | +6.7% |
| Feb 27, 2025 | 0.42 | 0.37 | +13.5% |
| Nov 12, 2024 | 0.40 | 0.37 | +8.1% |
| Aug 6, 2024 | 0.43 | 0.36 | +19.4% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
47No pass
Benjamin Graham
40No pass
Philip Fisher
55No pass
Peter Lynch
74Pass
Joel Greenblatt
10No pass
Charlie Munger
43No pass
Terry Smith
37No pass
Questions about Progyny
Is Progyny a good stock to buy?
A business with weak numbers, but the price is high. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Progyny AI analysis
What does Progyny do?
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. It is in Medical - Healthcare Information Services.
Does Progyny pay a dividend?
No. Progyny does not pay a dividend at the moment; in 2025 it returned $81.7 million to shareholders by buying back its own shares.
Is Progyny stock halal?
Yes. Progyny passes our halal screen: its business is permitted and its debt is 1% of its market value, under the 30% limit. How we check
How has Progyny stock done over the past year?
Up 48.2% over the past twelve months, to $36.18. It traded between $16.30 and $36.58, close to its high.
Who are Progyny's competitors?
The largest listed companies in the same industry are GE HealthCare Technologies, BrightSpring Health Services, Tempus AI and HealthEquity. The peers table on this page compares their profit, growth and price with Progyny's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.